XNAS
BTMD
Market cap48mUSD
Oct 08, Last price
1.17USD
1D
5.41%
1Q
-49.79%
IPO
-81.46%
Name
Biote Corp
Chart & performance
P/E
1.91
P/S
0.27
EPS
0.61
Div yield, %
—
Shrs. gr., 5y
37.08%
Rev. gr., 5y
10.52%
Revenues
192m
-2.52%
Net income
27m
+756.67%
CFO
35m
-22.21%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
Key people
Robert Peterson
Chief Financial Officer, Chief Business Officer · since 2025
Marc Beer
Executive Chairman of the Board · since 2021
Mary Conlon
Vice President - Business Development, General Counsel, Corporate Secretary · since 2022
Bret Christensen
Chief Executive Officer, Principal Executive Officer, Director · since 2025
Independent Director · since 2025
S. Mark Cone
Independent Director · since 2021
Independent Director · since 2021
Independent Director · since 2022
Dana Jacoby
Independent Director · since 2021
Independent Director · since 2022
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||